It's very difficult to speak of a probability, as I said. The only sure thing, the only time you really know, is when there's been a panel decision against Canada. Up to then, it's a question of risk and assessing risk.
As I said earlier, we've looked at the proposed amendments that would eliminate elements such as the capture WTO notifications, and at the information that wouldn't necessarily be provided, such as recipient country, the drug amounts, the delivery dates, and so on. Those are elements that draw inspiration from the WTO waiver, which in turn is what protects you from the obligations in the TRIPS agreement. So the argument is that if you're not fully respecting the waiver, you could be in violation of elements of the TRIPS agreement itself, and that's a risk. I can't characterize the risk beyond that.